MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 16, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today announced that it will provide a corporate

MONROVIA, Calif. --(BUSINESS WIRE)--Feb. 2, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two

MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 11, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced 2022 corporate priorities and anticipated

MONROVIA, Calif. --(BUSINESS WIRE)--Jan. 6, 2022-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate in a

MONROVIA, Calif. --(BUSINESS WIRE)--Dec. 12, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced updated data from its Phase 1 dose-escalation

-- Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products -- -- Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 19, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two

-- Vudalimab was generally well-tolerated; objective responses observed across multiple tumor types -- -- Confirmed partial responses observed in two of four evaluable castration-resistant prostate cancer patients with measurable disease -- -- Additional complete response observed in patient with

MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 12, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced the presentation of new data from multiple

-- Management to Host Conference Call at 4:30 p.m. ET Today -- MONROVIA, Calif. --(BUSINESS WIRE)--Nov. 8, 2021-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases,